Patel V. Mahesh's Insider Trades & SAST Disclosures
Patel V. Mahesh's most recent trade in Lipocine Inc was a trade of 16,371 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Patel V. Mahesh.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lipocine Inc | Patel V. Mahesh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 16,371 | 149,039 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 10,320 | 132,688 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | V. Mahesh Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 26,691 | 149,039 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 4,893 | 112,311 (0%) | 0% | 0 | Common Stock | |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 5.03 per share. | 25 May 2023 | 8,706 | 107,418 (0%) | 0% | 5.0 | 43,791 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.32 per share. | 24 Mar 2023 | 150,000 | 1,678,090 (3%) | 0% | 0.3 | 48,000 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.33 per share. | 17 Mar 2023 | 50,000 | 1,528,090 (3%) | 0% | 0.3 | 16,500 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 300,000 | 2,542,395 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 112,500 | 2,242,395 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.39 per share. | 14 Nov 2022 | 75,000 | 1,478,090 (3%) | 0% | 0.4 | 29,250 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.41 per share. | 27 Sep 2022 | 100,000 | 1,403,090 (2%) | 0% | 0.4 | 41,000 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 0.77 per share. | 16 May 2022 | 50,000 | 1,303,090 (2%) | 0% | 0.8 | 38,495 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 287,500 | 287,500 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 1.09 per share. | 18 Nov 2021 | 25,000 | 1,253,090 (2%) | 0% | 1.1 | 27,250 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 28 Dec 2020 | 275,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2020 | 375,000 | 375,000 | - | - | Stock Option (Right to Buy) | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 45,000 | 45,000 | - | - | Restricted Stock Unit | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 45,000 | 1,243,090 (2%) | 0% | 0 | Common Stock | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.35 per share. | 15 Dec 2020 | 15,000 | 1,228,090 (2%) | 0% | 1.4 | 20,250 | Common Stock |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 145,000 | 1,118,612 (2%) | 0% | 0 | Common Stock | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 145,000 | 145,000 | - | - | Restricted Stock Unit | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 122,978 | 122,978 | - | - | Restricted Stock Unit | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 122,978 | 1,198,090 (2%) | 0% | 0 | Common Stock | |
| Lipocine Inc | Mahesh V. Patel | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.57 per share. | 04 Dec 2020 | 43,500 | 1,075,112 (2%) | 0% | 1.6 | 68,134 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges